Compare ACADIA Pharmaceuticals Inc. (ACAD) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs HSBC Holdings plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while HSBC Holdings plc trades at $95.71 (market cap $329.01B). The key difference: HSBC Holdings plc is far larger — about 73.3× ACADIA Pharmaceuticals Inc.'s market cap, and HSBC Holdings plc pays a 3.85% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HSBC | |
|---|---|---|
Market Cap | $4.49B | $329.01B |
Sector | Health | Technology |
52-Week High | $28.06 | $98.74 |
52-Week Low | $20.06 | $61.30 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
HSBC trades at $98.74, up 2.03% with bullish technical indicators and strong earnings momentum. The stock shows consistent earnings beats with Q1 2026 EPS of $2.20 exceeding expectations. Recent developments include strategic reviews of non-core businesses and AI partnerships with Google Cloud. Valuation metrics include a P/E of 16.32 and P/B of 1.72, while maintaining a 30.81% net income margin.
HSBC presents a balanced investment case with solid fundamentals and strategic repositioning offset by regulatory risks and market volatility. The bank's focus on core markets and AI integration supports growth potential, though recent regulatory penalties and business exits warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
